This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

John P. Blass, MD, PhD; Andrea C. Baker; Li-wen Ko, BVM, PhD; Ronald S. Black, MD

Arch Neurol. 1990;47(8):864-869.

Abstract
• Since previous studies have suggested that the coupling of oxidation to phosphorylation is impaired in Alzheimer brain and fibroblasts, the effects of carbonyl cyanide m-chlorophenylhydrazone, a hydrazone known to uncouple mitochondrial oxidative phosphorylation, were tested on the development of immunoreactivity with antibodies to "Alzheimer antigens" in cultured fibroblasts from cognitively intact subjects. The fibroblasts were exposed for 10 to 14 days to a medium (DMd) modeled on media that favor neuronal differentiation in fetal brain cultures. The addition of a 10-µm concentration of carbonyl cyanide m-chlorophenylhydrazone to the DMd culture medium increased by more than 10-fold the proportion of cells reacting immunocytochemically with antibodies to paired helical filaments and by 157-fold the proportion of cells reacting with the Alz-50 monoclonal antibody. These observations suggest that the oxidative abnormalities previously described in tissues from patients with Alzheimer's disease may contribute to the accumulation of abnormal cytoskeletal materials in this disorder.

Author Affiliations
From the Altschul Laboratory for Dementia Research, Burke Rehabilitation Center, White Plains, NY.

Footnotes
Accepted for publication February 6, 1990.

Presented in part at the Dahlem Conference, Berlin, Germany, December 1987; at the International Conference on Alzheimer's Disease, Las Vegas, Nev, September 1988; at the annual meeting of the Society for Neuroscience, New Orleans, La, November 1987 and Toronto, Canada, November 1988; at the Fondation Ipsen Conference, Toulouse, France, April 1989; and at the International Psychogeriatric Congress, Tokyo, Japan, September 1989.

Reprint requests to the Altschul Laboratory for Dementia Research, Burke Rehabilitation Center, 785 Mamaroneck Ave, White Plains, NY (Dr Blass).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Mitochondrial Abnormalities in Alzheimer's Disease
Hirai et al.
J. Neurosci. 2001;21:3017-3023.
ABSTRACT | FULL TEXT  

Acceleration of phosphatidylcholine synthesis and breakdown by inhibitors of mitochondrial function in neuronal cells: a model of the membrane defect of Alzheimer's disease
FARBER et al.
FASEB J. 2000;14:2198-2206.
ABSTRACT | FULL TEXT  

Compromised mitochondrial function leads to increased cytosolic calcium and to activation of MAP kinases
Luo et al.
Proc. Natl. Acad. Sci. USA 1997;94:9705-9710.
ABSTRACT | FULL TEXT  

Plasma and Red Blood Cell Thiamine Deficiency in Patients With Dementia of the Alzheimer's Type
Gold et al.
Arch Neurol 1995;52:1081-1086.
ABSTRACT  

Pharmacotherapy of Cognitive Impairment in Alzheimer's Disease: A Review
Patel
J Geriatr Psychiatry Neurol 1995;8:81-95.
ABSTRACT